Amsterdam’s VectorY Therapeutics raises €74.5 million to tackle ALS and other neurodegenerative diseases
VectorY Therapeutics, an Amsterdam-based BioTech developing vectorised antibody therapies for neurodegenerative diseases, has raised €74.5 million ($83.5 million) in new financing. This new financing round saw participation from a number of new investors, including Angelini Ventures, the Dutch deve
<p>VectorY Therapeutics, an Amsterdam-based BioTech developing vectorised antibody therapies for neurodegenerative diseases, has raised €74.5 million ($83.5 million) in new financing. This new financing round saw participation from a number of new investors, including Angelini Ventures, the Dutch deve</p>